GolimumabIs is a monoclonal antibody that can bind soluble and transmembrane TNF, thereby blocking the binding and activity of TNF-α receptor (144), A previous study found that after stopping the previously used TNF-α antagonist, the use of golimumab improved the signs, symptoms, and physical functions, mainly by improving the cardiovascular system (CVS) and endothelial function by reducing arterial wall hardness and atherosclerosis (145); however, the cost is high, and the risk of infection is high. Here, TNF is linked to atherosclerosis.